Moreover, TRPM2 inhibitor‐based antibody‐drug conjugations (ADCs) or targeted nanoparticle drug delivery of TRPM2 inhibitors are other options for TRPM2‐targeted cancer therapy via reducing its systemic effects. The gene discussed is TRPM2; the disease is cancer.